TriPath Imaging, Inc.
This article was originally published in The Gray Sheet
PMA supplement is submitted to FDA covering use of the AutoPap automated primary Pap smear slide screening system with cytology samples prepared using the Prep automated, liquid-based Pap smear sample preparation system. TriPath is the new name for the recent combination of Prep system developer AutoCyte and AutoPap maker NeoPath under a June merger completed Oct. 1 (1"The Gray Sheet" June 14, p. 15). The Prep system was approved June 17 to replace conventional Pap smear preparation in primary screening for cervical cancer but not specifically for use with AutoPap, which was approved for initial screening of conventional slides in May 1998
You may also be interested in...
AutoCyte is hoping that its acquisition of NeoPath, a stock-swap transaction valued at over $100 mil., will result in a 50% share of the U.S. Pap smear market.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.